CRP and COVID-19: The usage of tocilizumab was stratified by severity of COVID-19; only those patients with signs of advanced systemic inflammation (hypoxia and C-reactive protein ≥75 mg/L) were randomized and treated with tocilizumab in addition to glucocorticoids.